Wipfli Financial Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Wipfli Financial Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$2K	Buy	+73	New	+$2.02K	﹤0.01%	2345

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wipfli Financial Advisors's RETA Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2022: 73 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #2345 among its holdings.

159 funds tracked by Wall St. Rank hold RETA as of Q3 2022.

Wipfli Financial Advisors held 73 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $2K as of Q3 2022.
Reata Pharmaceuticals, Inc. Class A Common Stock was a new Wipfli Financial Advisors position in Q3 2022.
Reata Pharmaceuticals, Inc. Class A Common Stock made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2345 holding.
159 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.